| アブストラクト | OBJECTIVE: Weight loss is conditionally recommended for gout management; however, its impact on incident gout and recurrent gout flares among individuals who were overweight and obese remains unknown. We investigate the relationship between weight loss rate following treatment with anti-obesity medications and the risk of incident gout and recurrent gout flares among individuals who were overweight or obese. METHODS: Using data from the Health Improvement Network, we selected individuals aged 18 and older who were overweight or obese and started anti-obesity medication. We emulated a target trial to examine the association of different weight loss rates, slow (2%-5%), moderate (5%-10%), or fast (>/=10%), within the first year of treatment with incident gout and recurrent gout flares during a 5 year follow-up period. RESULTS: Among 131,000 participants without gout being treated with orlistat, the 5-year risk of incident gout was 1.6% for those with weight gain or stability, compared with 1.5%, 1.3%, and 1.2% for those with slow, moderate, and fast weight loss, respectively. Compared with the group with weight gain or stability, the hazard ratios were 0.91 (95% confidence interval [CI] 0.81-1.01), 0.82 (95% CI 0.72-0.92), and 0.73 (95% CI 0.62-0.86) for those with a slow, moderate, and fast rate of weight loss, respectively. Similar results were observed for the recurrent gout flares among 3,847 individuals with overweight or obese with gout treated with orlistat. CONCLUSION: A higher rate of weight loss after receiving treatment with orlistat within 1 year was associated with lower risks of incident gout and lower rates of recurrent gout flares among overweight or obese people. |
|---|
| ジャーナル名 | Arthritis & rheumatology (Hoboken, N.J.) |
|---|
| Pubmed追加日 | 2024/9/20 |
|---|
| 投稿者 | Wei, Jie; Wang, Yilun; Dalbeth, Nicola; Xie, Junqing; Wu, Jing; Zeng, Chao; Lei, Guanghua; Zhang, Yuqing |
|---|
| 組織名 | Xiangya Hospital, Central South University, the Hunan Key Laboratory of Joint;Degeneration and Injury, the Key Laboratory of Aging-Related Bone and Joint;Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital,;Central South University, and the Xiangya School of Public Health, Central South;University, Changsha, China.;Degeneration and Injury, and the Key Laboratory of Aging-Related Bone and Joint;Central South University, Changsha, China.;University of Auckland, Auckland, New Zealand.;University of Oxford, Oxford, United Kingdom.;The Hunan Key Laboratory of Joint Degeneration and Injury and Key Laboratory of;Aging-Related Bone and Joint Diseases Prevention and Treatment, Ministry of;Education, Xiangya Hospital, Central South University, Changsha, China.;Central South University, and the National Clinical Research Center for Geriatric;Disorders, Xiangya Hospital, Central South University, Changsha, China.;The Mongan Institute, Massachusetts General Hospital, Harvard Medical School,;Boston. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39300602/ |
|---|
